Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Praxis Precision Medicines Inc
(NQ:
PRAX
)
41.20
-1.34 (-3.16%)
Streaming Delayed Price
Updated: 10:08 AM EDT, May 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Praxis Precision Medicines Inc
< Previous
1
2
3
4
5
Next >
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
November 28, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
November 16, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Where Praxis Precision Medicine Stands With Analysts
October 03, 2023
Via
Benzinga
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium
November 02, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
October 02, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
What 5 Analyst Ratings Have To Say About Praxis Precision Medicine
August 10, 2023
Via
Benzinga
Recap: Praxis Precision Medicine Q1 Earnings
May 11, 2023
Via
Benzinga
Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023
September 27, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
September 19, 2023
Via
Benzinga
Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress
August 31, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
August 28, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Top 5 Health Care Stocks That May Fall Off A Cliff
August 23, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 09, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
August 08, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
August 07, 2023
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.
Via
Benzinga
Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
August 07, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference
August 03, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
June 22, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering
June 15, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
June 15, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
June 09, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
June 02, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
June 02, 2023
Via
Benzinga
Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference
June 02, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Says PRAX-628 Can Potentially Be The Best-In-Class Treatment For Focal Epilepsy
May 11, 2023
Praxis Precision Medicines Inc (NASDAQ: PRAX) announced topline results from the PRAX-628 Phase 1 healthy volunteer study evaluating single ascending doses (SAD) and
Via
Benzinga
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
May 11, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.